University of Buffalo Clinical and Translational Science Institute

CTSA UL 1摘要 布法罗翻译联盟（BTC），其中包括布法罗大学（UB）健康科学 学校，我们地区的主要医疗机构，四个重点研究机构和五个有影响力的社区 合作伙伴，已经开始了一项全面的战略计划，为临床和 翻译研究，以回应我们的社会需求。布法罗是纽约州第二大人口城市 约克州有着丰富的文化历史。2018年布法罗代表性不足的少数民族比例（50%） 与美国2050年的预测相似，使布法罗成为美国30年后的缩影。 我国人口中同样比例的人经历着健康差距。我们CTSA中心的愿景是 创新的研究，在整个翻译频谱，以改善我们的社区和国家的健康。 我们将开发、测试和分享新的方法，以吸引难以吸引的人群，并减少健康问题。 我们的社会代表着“未来的人口”。在我们的愿景指导下，CTSA 自我们的CTSA于2015年8月首次获得资助以来， 临床和转化研究的增长。此外，在过去的一年里，UB医学院已经进入 一个壮观的新建筑和我们的临床合作伙伴，Kaleida健康，该地区最大的医疗保健系统， 开设了新的Oishei儿童医院，无论是在布法罗尼亚加拉医学院校园，并连接到 临床和转化研究中心完全致力于临床和转化研究，于2009年开业。 2012.该地区医疗保健和研究的快速持续增长导致了 新的21世纪世纪学术健康中心，医疗保健，医学教育，临床和翻译 在布法罗中心的一个校园进行研究，创建一个基础，以提高我们的CTSA的影响，甚至 进一步.在启动我们的CTSA的同时，我们通过主办 并将创新实验室作为团队科学工具进行测试，与多个中心合作， 我们与CTSA联盟开发的研究障碍和共享工具，包括新的健康 信息学工具。我们的CTSA有五个雄心勃勃但可以实现的目标，包括：1）加速创新 与社区、区域利益攸关方和国家联盟合作的团队进行转化研究; 2)培养一支优秀的、多样化的劳动力队伍，以促进发现的翻译; 3）加强对特殊知识的包容性， 整个生命周期的人群和难以参与的人群; 4）简化临床研究过程 注重质量和效率，重点是多中心研究; 5）开发，测试和共享生物医学 信息学工具，以整合来自多个来源的数据，以加快翻译。以我们的愿景为指导， 研究，以改善我们的社区和国家的健康，我们将继续我们的势头，扩大 转化研究，培训我们多样化的员工队伍，简化流程，参与我们的社区，并积极 为国家财团做贡献。 CTSA多样性补充：细菌源性主动脉内皮功能障碍促进动脉粥样硬化 戴伦莱娅Rodriquez，候选人为这一多样性补充是西班牙裔背景和完成 这一补充奖将使他获得学术知识，研究技能和专业 在临床和转化研究领域的发展。该提案包含了母公司的目标 CTSA UL 1奖：1）培养优秀的多元化员工队伍，以推进翻译和健康相关研究 （2）加强对特殊人群的包容。 为了完成拟议的补充研究，Dayron将利用以下CTSA核心： ·生物统计学，流行病学和研究设计（BERD）核心：Dayron将利用专业知识 并得到他的导师Greg Wilding博士（BERD主任）的支持，以进行适当的统计实验设计 分析所有实验数据。他还将完成BERD统计研讨会和BERD临床 试验研讨会系列，以获得适用于临床和转化研究方面的能力。 ·劳动力发展核心：Dayron将完成系列研讨会（每个研讨会包含4-8名个人 a）负责任的研究行为，B）科学交流，c）翻译 团队合作和d）良好的临床实践。 完成每个系列后，Dayron将获得数字徽章，并完成所有这些 讲习班将获得他的CTSI临床和转化研究基本微证书。 ·临床研究促进核心：Dayron和我们的研究团队将与促进者合作，继续 成功的招募策略，包括传单和广告，以及访问患者数据库， 作为布法罗研究登记处招募当地志愿者。与社区参与协商 核心将促进从性别和不同种族中适当招募受试者 背景，以增加我们的受试者群体和收集的数据的稳健性。 ·实验室设施核心。Dayron将使用共聚焦显微镜和流式细胞仪， 下一代测序和表达设施用于完成所提出的实验。

CTSA UL1 Abstract The Buffalo Translational Consortium (BTC), which includes the University at Buffalo (UB) health sciences schools, the major healthcare institutions in our region, four key research institutes and five influential community partners, have embarked on a comprehensive strategic plan to build a strong foundation for clinical and translational research in response to our community needs. Buffalo is the second most populous city in New York State and has a rich cultural history. The proportion of underrepresented minorities in Buffalo in 2018 (50%) parallels that projected for the US in 2050, making Buffalo a microcosm of what the US will look like in 30 years. A similar proportion of our population experiences health disparities. The vision for our CTSA hub is to perform innovative research across the translational spectrum to improve the health of our community and the nation. We will develop, test and share novel approaches to engage difficult-to-engage populations and reduce health disparities in our community, which represents a “population of the future”. Guided by our vision, the CTSA has catalyzed a transformation of our environment since our CTSA was first funded in August 2015 with remarkable growth in clinical and translational research. Further, in just the past year, the UB medical school has moved into a spectacular new building and our clinical partner, Kaleida Health, the largest healthcare system in the region, opened the new Oishei Children’s Hospital, both on the Buffalo Niagara Medical Campus and connected to the Clinical and Translational Research Center devoted entirely to clinical and translational research that opened in 2012. This rapid and continuing trajectory of growth in healthcare and research in the region has resulted in a new 21st century Academic Health Center with healthcare, medical education and clinical and translational research on one campus in the heart of Buffalo, creating a foundation to enhance the impact of our CTSA even further. While launching our CTSA, we have prioritized participation in the national consortium through hosting and testing Innovation Labs as a team science tool, working with multiple hubs on initiatives to solve translational research barriers and sharing tools that we have developed with the CTSA consortium, including novel health informatics tools. Our CTSA has five ambitious but achievable aims, including: 1) Accelerate innovative translational research with teams that engage communities, regional stakeholders and the national consortium; 2) Train an excellent, diverse workforce to advance translation of discoveries; 3) Enhance inclusion of special populations across the lifespan and difficult-to-engage populations; 4) Streamline clinical research processes focusing on quality and efficiency with emphasis on multisite studies; 5) Develop, test and share biomedical informatics tools to integrate data from multiple sources to speed translation. Guided by our vision to perform research to improve the health of our community and the nation, we will continue our momentum to expand translational research, train our diverse workforce, streamline processes, engage our community, and actively contribute to the national consortium. CTSA Diversity Supplement: Bacterial Derived Aortic Endothelial Dysfunction to Promote Atherosclerosis Dayron Leya Rodriquez, the candidate for this diversity supplement is of Hispanic background and completion of this supplement award will allow him to gain academic knowledge, research skills and professional development in the areas of clinical and translational research. This proposal encompasses aims of the parent CTSA UL1 award to 1) train an excellent diverse workforce to advance translational and health-related research with 2) ehnanced inclusion of special populations. To complete the proposed supplemental research, Dayron will utilize the following CTSA cores: • Biostatistics, Epidemiology and Research Design (BERD) Core: Dayron will leverage the expertise and support of his mentor Dr. Greg Wilding (Director of BERD), for appropriate statistical experimental design and analysis of all experimental data. He will also complete the BERD Statistical workshops and BERD Clinical Trials workshops series to gain competency in aspects applicable to clinical and translational research. • Workforce Development Core: Dayron will complete workshop series (each containing 4-8 individual workshops) in the areas of a) Responsible Conduct of Research, b) Scientific Communication, c) Translational Teamwork and d) Good Clinical Practice. Following completion of each series, Dayron will be awarded a Digital Badge and with completion of all these workshops will earn his CTSI Basic Micro-credential in Clinical and Translational Reseach. • Cinical Research Facilitation Core: Dayron and our research team will work with faciltators to continue successful recruitment strategies including flyers and advertising as well as access to patient databases such as the Buffalo Research Registry to recruit local volunteers. Consultation with the Community Engagement Core will facilitate appropriate community recruitment of subjects from both genders and diverse ethnic backgrounds to increase the robustness of our subject population and collected data. • Laboratory Facility Cores. Dayron will utilize the Confocal Microscope and Flow Cytometry Facility and Next Generation Seqeuncing and Expression Facility for completion of the proposed experiments.